[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wound-of-skin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wound-of-skin":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,47,72,101,128,150,172,210,235,257,277],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100554332","benefit-of-hypnosis-on-pain-during-stitches-in-emergency-room-100554332",false,"NCT06497712","BEnefit of HYpnosis on Pain During Stitches in Emergency Room","BEnefit of HYpnosis on Pain During Stitches in Emergency Room: The BE-HYPER Study","BE-HYPER","Inclusion criteria\n\n* Age \\> 18 years old\n* Admitted in the emergency department of Clermont-Ferrand University Hospital\n* Stitchable wound\n* Patient's agreement\n\nExclusion criteria\n\n* Pregnancy\n* Breast feeding\n* Refusal to participate\n* Patient not able to participate\n* Patients under guardianship, curatorship, deprived of liberty or safeguard of justice.\n* History of cardiac rhythm disorders (atrial fibrillation, pacemaker)\n* Psychotic disorder\n* Age \\\u003C 18 years old\n* Surgery needed\n* Patients who don't speak French\n* Wound of the eyelids, nose, ears or mouth\n* Deaf patients\n* Patients without a social security coverage\n* Nitrous oxyde use\n* Substance abuse\n* Head trauma with GSC ≤ 14\n* Patient with endocrine diseases on the cortisol axis","ALL","18 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"NA","Suturing is a daily practice in the emergency department, but it can be painful and stressful for patients. Hypnosis is increasingly used as a complement to the usual painkillers. The aim of our study was to investigate the impact of hypnosis on stitch placement in emergency department patients presenting with lacerations assessed by heart rate variability.",[27],"Wound of Skin",[29,30,31,32,33],"hypnosis","wound","stitches","pain","sinusal variability of cardiac frequency","RECRUITING","2026-05-29",{"date":37,"type":38},"2026-06-02","ACTUAL",{"date":40,"type":38},"2025-05-15",{"date":42,"type":21},"2028-05-15",{"name":44,"class":45},"University Hospital, Clermont-Ferrand","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100599075","truelok-elevate-pmcf-study-100599075","NCT07079774","TrueLok Elevate PMCF Study","Post-Market Clinical Follow-up Study of the TrueLok Elevate Transverse Bone Transport System for the Treatment of Lower Limb Ulcers as Soft Tissue Defects","Inclusion Criteria:\n\nAged 18 years or older at the time of surgery Willing and able to sign and date the study-specific informed consent form in accordance with national and institutional ethics requirements Willing and able to comply with requirements of the protocol, including follow-up requirements Indicated for surgical intervention using the TrueLok Elevate Transverse Bone Transport System for the treatment of soft tissue defects in the form of lower limb ulcers\n\nPresence of a chronic ulcer, defined as:\n\n* Present for at least 3 months, and\n* Unresponsive to standard non-surgical or surgical wound management, including but not limited to debridement, negative pressure wound therapy (VAC), offloading, antibiotics, or vascular optimisation\n\nExclusion Criteria:\n\nMental or cognitive impairment or physiological or behavioural conditions that, in the opinion of the investigator, would preclude reliable adherence to postoperative care instructions, follow-up assessments, or study procedures\n\nKnown or presenting with the following signs of a systemic inflammatory response syndrome (SIRS) as exhibiting two or more of the following conditions:\n\no\n\n* Heart rate \\>90 beats\u002Fmin\n* Respiratory rate \\>20 breaths\u002Fmin\n* PaCO2 \\\u003C32-mm Hg\n* White blood cell count \\>12.000 or \\\u003C4.000\u002Fcu mm\n* 10% immature (band) forms Known hypersensitivity or allergy to any material used in the TrueLok Elevate Transverse Bone Transport System (e.g., stainless steel, titanium) Current participation in another interventional clinical study that, in the opinion of the investigator, may interfere with the objectives or outcomes of this study Presence of active malignancy or systemic infection that, in the investigator's opinion, may interfere with wound healing or the study protocol Life expectancy of less than 12 months Simultaneous bilateral application of the TrueLok Elevate Transverse Bone Transport System Current incarceration at the time of enrolment Any condition or clinical circumstance that, in the opinion of the investigator, would make participation not in the best interest of the subject or would interfere with the study objectives",{"count":55,"type":21},153,"OBSERVATIONAL","The TrueLok Elevate Transverse Bone Transport System is a modular external fixation device designed for transverse bone transport. It promotes local vascular and wound healing through controlled corticotomy and gradual distraction. The system is intended for adult patients with bony and\u002For soft tissuedefects.",[27,59,60],"Ulcers","Soft Tissue Defect","2026-03-31",{"date":63,"type":38},"2026-04-01",{"date":65,"type":38},"2025-11-24",{"date":67,"type":21},"2028-11-24",{"name":69,"class":70},"Orthofix s.r.l.","INDUSTRY",5,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":90,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":46},"100618245","healing-electroceutical-dressing-for-the-recovery-of-open-wounds-hero-100618245","NCT07329114","Healing Electroceutical Dressing for the Recovery of Open Wounds (HERO)","Prospective, Unblinded, Randomized, Controlled Investigation to Evaluate the Clinical Efficacy of PowerHeal™ Bioelectric Bandage in Managing Infected Traumatic Wounds","HERO","Inclusion Criteria:\n\n1. Female and male participants 18-105 years of age\n2. Hospital admission (or boarding in an emergency department or other area awaiting hospital admission) at participating clinical sites in Ukraine\n3. At least one infected traumatic wound(s) between 20-40 cm2 in size. Probable or confirmed wound infection(s) will be determined by on-site physicians' clinical judgment and the presence of two or more of the following clinical indicators of wound infection:\n\n   1. Presence of worsening pain (from the moment of injury)\n   2. Erythema (redness)\n   3. Warmth (heat)\n   4. Edema (swelling)\n   5. Purulent exudate (drainage)\n   6. Delayed healing\n   7. Discoloration\n   8. Friable granulation\n   9. Foul odor\n   10. Wound margin breakdown or necrosis with or without fever\n   11. Pustules, vesicles, boils\n4. Participant or legal representative provides written informed consent prior to investigation procedures\n5. Participant understands and agrees to adhere to planned investigation procedures\n\nExclusion Criteria:\n\n1. Allergy to silver or zinc\n2. Women who are pregnant or nursing\n3. Women of childbearing potential without a documented negative pregnancy test during the current hospitalization or women of childbearing potential who refused pregnancy testing during screening\n4. Sponsor or contract research organization (CRO) staff directly involved in the conduct of the investigation, and site staff supervised by the investigator, and their respective family members\n5. \\> 60 days from the initial traumatic injury\n6. Known prisoner\n7. The patient is expected to be discharged from the hospital within the next 24 hours\n8. Medical condition other than the acute traumatic wound (and its manifestations) that is likely to result in death within 14 days of randomization\n9. Moribund condition, defined as life expectancy less than 48 hours from randomization\n10. Patients undergoing comfort care measures only such that treatment focuses on end-of-life symptom management over prolongation of life\n11. Expected inability or unwillingness to participate in study procedures\n12. In the opinion of the investigator, participation in the investigation is not in the best interest of the patient\n\nNote: Allergies to parabens and acrylates will also be considered. While they are not direct exclusions, participants with these allergies should avoid being enrolled.","105 Years",{"count":82,"type":21},150,[24],"The goal of this clinical trial is to determine whether the wireless electroceutical dressing (WED) called PowerHeal™ Bioelectric Bandage, improves care of infected wounds by clearing the infection and helping the wound heal better.\n\nThe main hypotheses it aims to answer are:\n\n1. WED promotes wound closure, as determined by wound area measurement\n2. WED manages wound infection in civilian and military wounds in Ukraine, as determined by clinical assessment of wound infection by measuring the numbers and types of relevant microbes.\n\nResearchers will compare to see if PowerHeal™ Bioelectric Bandage the dressing used in the SOC group\n\nParticipants will get their dressings changed per the protocol, wound image and swab will be taken.",[86,87,88,27,89],"Wound Heal","Wound Infection","Wound Healing Delayed","Infections",[91],"bandage","2026-03-04",{"date":94,"type":38},"2026-03-06",{"date":96,"type":38},"2026-02-11",{"date":98,"type":21},"2027-08",{"name":100,"class":45},"Chandan Sen",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":46},"100541692","phase-2-4-aminopyridine-for-skin-wound-healing-100541692","NCT06333171","4-aminopyridine for Skin Wound Healing","Inclusion Criteria:\n\n* Otherwise healthy adult patients without skin conditions effecting the skin of the axilla or upper inner arm.\n* Cognitive ability to evaluate wound healing, report sensory and motor deficit during examination.\n* Eligible for standard of care plan for wound closure by secondary intention (normal healing without intervention).\n* Adults subject aged 18-70\n* Ability to give written informed consent.\n* Capable of safely coming in for follow up visits on all scheduled appointments.\n\nExclusion Criteria:\n\n* History of multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of hypersensitivity to AMPYRA® or 4-aminopyridine\n* Current use of aminopyridine medications, including other compounded 4-AP\n* Suspected renal impairment based on the Choyke questionnaire.\n* History of difficult compliance with timely follow up\n* Patients outside the age range\n* Unable to provide informed consent.\n* Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity).\n* Patients with a concomitant traumatic brain injury.\n* Patients unable to communicate.\n* Patients unwilling to complete the study requirements.\n* Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine.\n* Pregnancy, breastfeeding or incarcerated individuals.\n* Non-English speaking\n* Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds",true,"70 Years",{"count":82,"type":21},[111],"PHASE2","Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults.\n\nThe purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing.\n\nThe investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing.",[114,27,86,115],"Wounds","Wounds and Injuries",[117,118],"4 aminopyridine","wound healing","2025-09-01",{"date":121,"type":38},"2025-09-03",{"date":123,"type":21},"2025-09",{"date":125,"type":21},"2028-03",{"name":127,"class":45},"John Elfar",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":46},"100474819","suprathel-use-during-prolonged-field-care-to-promote-healing-and-reduce-the-need-for-grafting-of-burn-wounds-100474819","NCT05462860","Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds","Inclusion Criteria:\n\n* Male or Female ≥18 years and ≤75 years\n* Acute partial thickness burns by friction, contact, scalding from hot liquids and flame\n* TBSA total ≥2 %; burn treatment region of interest: all areas with partial-thickness burns excluding face, neck, scalp, and feet\n* TBSA 3rd ≤5 % (not to be included as burn treatment region of interest)\n* Subject is able and willing to sign Informed Consent or via legally authorized representative\n\nExclusion Criteria:\n\n* Study Wound due to electrical, radioactive, or frostbite-related injury\n* Infection of wounds in the study area at admission per Investigator or treating physician discretion\n* Pregnancy\u002Flactation\n* Subjects who are unable to follow the protocol or who are likely to be non-compliant\n* Participation in an active treatment arm of a burn wound related interventional study within 90 days of Screening Visit or during the study\n* Prisoners\n* Life expectancy less than 6 months\n* Subjects who are receiving steroids, chronic anticoagulants, or immune suppressive treatment","75 Years",{"count":136,"type":21},21,[24],"The purpose of this study is to determine the effect to which Suprathel® (Polymedics Innovations GmbH, Denkendorf, Germany) can reduce the need for grafting compared to Standard of Care (SoC). Furthermore, the study intends to evaluate if Suprathel® allows for a reduction of reduction of pain, infection, provider workload, scar development and costs compared to SoC.",[27,140],"Burns","2025-04-08",{"date":143,"type":38},"2025-04-10",{"date":145,"type":38},"2024-09-18",{"date":147,"type":21},"2026-06-29",{"name":149,"class":45},"The Metis Foundation",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":4},"100456469","manual-implantation-of-full-thickness-skin-microcolumns-100456469","NCT05223998","Manual Implantation of Full-Thickness Skin Microcolumns","Manual Implantation of Full-Thickness Skin Microcolumns for 'Donor-Free' Skin Renewal","Inclusion Criteria:\n\n* 8-85 years of age\n* 10-125 cm2 open wound on the scalp, neck, torso or extremities necessitating tissue coverage\n* Sufficiently healthy skin to serve as a donor site\n\nExclusion Criteria:\n\n* Wound area involving the face\\*\n* Wound area involving joints\\*\n* Pregnancy\n* Prisoner\n* Active wound infection at potential treatment sites\n* Exposed muscle, joint, tendon, or bone within the wound bed","85 Years",{"count":159,"type":21},10,[24],"The objective of this study is to validate the proof of concept regarding the approach of manual implantation of full-thickness skin microcolumns (FTSMs) as coverage for open wounds without creating an additional donor scar and while also capitalizing on the wound healing benefits offered by full-thickness skin grafts.",[27,140],"NOT_YET_RECRUITING","2024-10-17",{"date":166,"type":38},"2024-10-18",{"date":168,"type":21},"2024-11-04",{"date":170,"type":21},"2025-09-29",{"name":149,"class":45},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":192,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":46},"100458581","examining-the-effectiveness-of-dermgen-in-the-treatment-of-diabetic-foot-ulcers-in-first-nations-people-100458581","NCT05251480","Examining the Effectiveness of DermGEN™ in the Treatment of Diabetic Foot Ulcers in First Nations People","Examining the Effectiveness of DermGEN™ Versus Standard of Care in the Treatment of Diabetic Foot Ulcers in First Nations People Living in Northwestern Ontario Communities","Inclusion Criteria:\n\n* Participant and social support (e.g., family, caregiver) ready and willing to participate and comply with follow-up regime\n* Participant willing to be involved in self-care (e.g., keep dressing dry at home) required during treatment\n* Participant willing to wear Total Contact Cast (TCC) for wound off-loading during treatment\n* Participant or legal representative has read and signed the informed consent form\n* Documented stable Type I or II diabetes (HbA1C between 5.0 to 10 mmol\u002FL within 1 month prior to Day 0)\n* Ulcer has been present for a minimum of 2 weeks as of Day 0\n* Ulcer area is ≥2 cm2 prior to debridement at Day 0 of study\n* Ulcer extends through dermis and into subcutaneous tissue but without exposure of muscle, tendon, bone or joint capsule\n* Ulcer is free of dead tissue and clinical infection, and is comprised of healthy vascular tissue suitable for skin grafting on Day 0\n* Adequate perfusion to the extremity determined by at least one of the following:\n\nPalpable pedal pulses, Transcutaneous oxygen measurement at the dorsum of the foot ≥30 mm Hg, Ankle-brachial index ranging from 0.8 to 1.2, At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries\n\nExclusion Criteria:\n\n* The individual has any condition that seriously compromises their capacity to provide consent and answers questions related to this study.\n* Untreated infection of soft tissue or bone and\u002For autoimmune connective tissue disorders\n* Ulcer is over Charcot deformity (joints deformity of foot and ankle common in people with diabetes)\n* Body mass index ≥50 kg\u002Fm2\n* Ulcer is not classified as diabetes-related\n* Ulcer has tunnels or sinus tracts that cannot be completely debrided\n* Medical condition(s) that in the investigators' opinion make the patient inappropriate for study (e.g active liver disease)\n* Presence of malignant disease not in remission for 5 years or more\n* The individual is undergoing chemotherapy\u002Fradiation therapy\n* The individual received radiation therapy within 30 days of Day 0 of study\n* The individual is taking an immunosuppressant medication (e.g., corticosteroids, immunosuppression or cytotoxic agents), or is anticipated to require such agents during study\n* Presence of acute or chronic hepatitis, liver disease, anemia, serum albumin \\\u003C2.0 gm\u002FdL, or has alkaline phosphatase or LDH at twice the normal upper limit\n* Obvious clinical signs and symptoms of ongoing tissue infection (i.e., cellulitis) or bone infection (i.e., osteomyelitis)\n* Female individuals are pregnant at time or intend to get pregnant during study time\n* The individual has known allergies to antibiotics, such as penicillin and streptomycin\n* The individual is an active smoker (smoke one or more cigarette a day)\n* The individual has a history of a bleeding disorder or is taking blood thinner medication","80 Years",{"count":181,"type":21},120,[24],"The study will examine the effectiveness of a decellularized dermal matrix (i.e., DermGEN™) in improving wound healing, quality of life and associated costs of treatment of DFUs in First Nations people living in the Northwestern Ontario Communities. First Nations people with active diabetic foot (DFU) ulcer attending a wound care clinic located at the Rainy River district office. An interventional, two-arm, randomized, prospective study of (1) standard of care (control) vs. (2) DermGEN™ - a decellularized dermal matrix (treatment) will be used in the treatment and management of DFU. Patients will be randomized to each arm (n=60 per arm) based on power calculations using data from our Pilot study.",[185,186,187,188,189,27,190,191],"Diabetes Mellitus","Ulcer Foot","Ulcer Healing","Diabetic Foot Ulcer","Non-healing Wound","Wound; Foot","Tissue Injury",[193,188,189,194,195,196,197,198,199,200],"Diabetic Ulcer","Tissue Engineering","Regenerative Medicine","Decellularized Matrix","Acellular Dermal Matrix","Tissue Allograft","Indigenous Healing","Advanced Wound Care","2024-07-02",{"date":203,"type":38},"2024-07-03",{"date":205,"type":21},"2024-12-30",{"date":207,"type":21},"2026-12-01",{"name":209,"class":70},"DeCell Technologies Inc.",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":224,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":234},"100485995","a-clinical-investigation-to-follow-the-progress-of-exuding-chronic-venous-leg-ulcers-using-a-non-bordered-foam-dressing-100485995","NCT05608317","A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam Dressing","A Prospective, Open, Multi-Center, Interventional, Non-Comparative Clinical Investigation to Follow the Progress of Exuding Venous Leg Ulcers Using a Non-Bordered Foam Dressing","Inclusion Criteria:\n\n* Signed consent to participate (including consent for digital imaging)\n* Adult aged ≥18 years\n* Diagnosed with a chronic, exuding VLU\n* Exudate amount moderate to large\n* Wound size from 3 cm2 to 30 cm2, as determined by the clinician\n* ABPI (within 3 months) \\> 0.7. If ABPI \\> 1.4, then big toe pressure \\> 60 mmHg is required or an alternative measurement verifying normal distal arterial flow\n* Willing to be compliant with compression therapy\n\nExclusion Criteria:\n\n* Infected ulcer according to the judgment of the investigator defined as any wound condition requiring the prescription or continuation of systemic antibiotic therapy at enrollment\n* Circumferential wound\n* Known allergy\u002Fhypersensitivity to the materials of the dressing\n* Use of wound fillers",{"count":218,"type":21},20,[24],"The goal of this clinical trial to follow the progress of wounds in those with chronic venous leg ulcers while using a non-bordered foam dressing. The main objective is to follow the progress of these wounds over time from initial visit to each follow-up visit.\n\nParticipants will be asked to wear the dressing for up to 6 weeks of treatment or until healed, changed at every one-week interval.",[114,27,222,223],"Wound Leg","Venous Leg Ulcer",[223],"2024-05-03",{"date":227,"type":38},"2024-05-06",{"date":229,"type":38},"2022-11-08",{"date":231,"type":21},"2024-11-30",{"name":233,"class":70},"Molnlycke Health Care AB",3,{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":256},"100484479","a-clinical-investigation-to-follow-the-progress-of-exuding-chronic-wounds-using-mepilex-up-as-the-primary-dressing-100484479","NCT05588583","A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.","A Prospective, Open, Multi-Center, Interventional, Non-Comparative Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up","Inclusion Criteria:\n\n* Signed consent to participate (including consent for digital imaging)\n* Adult aged ≥18 years\n* Diagnosed with a chronic, exuding VLU or DFU\n* Exudate amount moderate to large\n* Wound size from 3 cm2 to 30 cm2 for VLU and ≥1 cm2 for DFU, as determined by the clinician\n* For VLU: ABPI (within 3 months) \\> 0.7. If ABPI \\> 1.4, then big toe pressure \\> 60 mmHg is required or an alternative measurement verifying normal distal arterial flow\n* For VLU: Willing to be compliant with compression therapy\n\nExclusion Criteria:\n\n* Infected ulcer according to the judgment of the investigator defined as any wound condition requiring the prescription or continuation of systemic antibiotic therapy at enrollment\n* Circumferential wound\n* Known allergy\u002Fhypersensitivity to the materials of the dressing\n* Patients participating in the DIPLO NBF study\n* Use of wound fillers",{"count":243,"type":21},68,[24],"The goal of this clinical trial is to follow the progress of wounds in those with venous leg ulcers and diabetic foot ulcers while using an absorbent dressing called Mepilex Up. The main objective is to follow the progress of these wounds over time from initial visit to each follow-up visit.\n\nParticipants will be asked to wear Mepilex Up dressing for up to 6 weeks of treatment or until healed, changed at every one-week interval.",[114,27,222,190,188,223],[188,223],"2023-04-18",{"date":250,"type":38},"2023-04-20",{"date":252,"type":38},"2022-10-31",{"date":254,"type":21},"2024-03",{"name":233,"class":70},4,{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":46},"100312380","reducing-surgical-site-infection-rates-using-an-alternative-sternal-dressing-100312380","NCT03346694","Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing","Inclusion Criteria:\n\n* Participants who will undergo cardiac surgery via a sternotomy incision.Inclusion criteria will be patients having surgical valve, CABGs, aortic dissection, myectomy and myotomy, Cox MAZE, Myocardial bridge Un-roofing\n\nExclusion Criteria:\n\n* Patients undergoing heart transplants, Ventricular Assist Device (VAD), with postoperative courses complicated by tamponade, take-backs, and open chest incisions will also be excluded.",{"count":264,"type":21},660,[24],"This study will evaluate two alternative dressings compared to a standard Island dressing presently in use at Stanford Hospital to determine reductions in surgical site infection (SSI) rates among cardiac surgery patients. Cardiovascular surgery patients who will have a sternotomy incision as a routine part of their surgery will be approached to voluntarily participate. Participants will be randomized to one of three dressing to determine which dressing has the lowest rate of sternal wound infection. The investigators will also assess the impact of alternative dressing use on hospital 30-day readmission rates related to SSI.",[27],"2022-10-24",{"date":270,"type":38},"2022-10-26",{"date":272,"type":38},"2018-05-01",{"date":274,"type":21},"2035-05-01",{"name":276,"class":45},"Stanford University",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":22,"phases":285,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":46},"100455945","phase-4-pilot-study-kerastat-gel-for-topical-delivery-of-morphine-for-management-of-non-healing-painful-open-wounds-and-ulcers-100455945","NCT05217160","Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers","Inclusion Criteria:\n\n1. Subjects age 18 or older able to provide informed consent.\n2. Ulcer size 1-300 cm2\n\n4\\. Undermining\u002Ftunneling \\\u003C3 cm from wound margin 5. Grossly free of necrotic and\u002For infected tissue 6. Baseline minimum of 2 on VAS pain scale\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria will be excluded from the study:\n\n1. Known allergy to the standard of care or any of the ingredients in KeraStat® Gel or to morphine\n2. Wound has heavy or high-volume exudate or necrotic tissue\n3. Clinical signs of infection or contamination of the wound\n4. Subjects unable to complete the VAS pain score in pain journal\n5. Pregnant or nursing\n6. Prisoner\n7. Any condition the Investigator determines will compromise subject safety or prevent the subject from completing the study",{"count":284,"type":21},24,[286],"PHASE4","This study is intended to provide information from subjects who currently have painful, chronically open wounds and assess the pain reduction capacity of KeraStat® Gel with Morphine. In gathering data from subjects who have baseline pain from their chronically open wounds, the investigators can then evaluate the capacity of KeraStat® Gel plus Morphine in reducing the subjects daily pain levels, pain associated with dressing changes, and pain medication consumption.",[27,140],"2022-01-19",{"date":291,"type":38},"2022-02-01",{"date":293,"type":38},"2021-05-11",{"date":295,"type":21},"2022-05-31",{"name":149,"class":45}]